嘉必優(688089.SH):基於合成生物學技術,公司目前已經開發出系列HMO產品
格隆匯5月16日丨嘉必優(688089.SH)在投資者互動平台表示,公司以技術創新為根本驅動力,已打通合成生物學全技術鏈條,逐步形成了以計算生物學、生物信息學為核心技術能力的生物數據分析與處理平台,以基因工程、代謝工程、酶工程、細胞工程為核心技術能力的生物合成平台,以細胞生物學、生物醫學、多維組學可視化分析為核心能力的功能驗證平台,從產品開發到應用技術,公司的合成生物學研發技術能力得到進一步的提升。基於合成生物學技術,公司目前已經開發出系列HMO產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.